• Aarti Drugs revenue rises 34.34% yoy to Rs544.67cr in Q1

    • July 29, 2020
    • Posted By : admin
    • 0 Comment

    Aarti Drugs Limited on Monday announced the financial results of the quarter ended June 2020. The company recorded consolidated quarterly revenue of Rs544.67cr with yoy increase of 34.34%. API segment contributed approximately 85% and formulation around 15% of the total consolidated revenues.

    Domestic sales of the API segment grew by ~28.19% and exports by 29.13%. Around 50% of the yoy growth in the API segment was due to volume growth. Formulation segment revenues grew by around 89.49% on a year-on-year basis on the account of high export growth.

    Consolidated EBITDA for the quarter ended June 2020 stood at Rs135.23cr, up by 146.89% and consolidated profit after tax for the quarter ended June 2020 was Rs85.45cr, up by 280.63% yoy. Consolidated EBITDA margin improved to 24.83%.

    “Despite challenges faced during Covid-19 lockdown, the company was able to maintain good operational efficiency which along with good realization in selling prices led to increased gross margins. Debt/Equity ratio of the Company reduced further down to 0.55 as of June’2020 on a consolidated basis,” company said.

    The company has already scaled up its anti-diabetic and anti-inflammatory capacity and it will give impetus to revenue growth in FY21. This would be further supported by good growth in formulation exports.


You Might Also Like

No comments found



error: Content is protected !!